Thomas Beatrous
Radiation Oncology · Montgomery, ALNPI 1306853700
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $575 and has fallen 96.8% since, to $19 in 2025.
Across 90 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dova Pharmaceuticals$214
- Novartis$206
- Novocure Inc.$111
- Octapharma USA, Inc.$109
- Bristol Myers Squibb$73
- Merck$73
- plus $929 from 26 others
What the payments were for
- Food & beverage$1,67698%
- Education$402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dova Pharmaceuticals | 10 | $214 |
| Novartis | 12 | $206 |
| Novocure Inc. | 5 | $111 |
| Octapharma USA, Inc. | 2 | $109 |
| Bristol Myers Squibb | 4 | $73 |
| Merck | 4 | $73 |
| Jazz Pharmaceuticals Inc. | 4 | $72 |
| Sobi, Inc | 2 | $71 |
| Eisai Inc. | 4 | $64 |
| Regeneron Healthcare Solutions, Inc. | 3 | $58 |
| Johnson & Johnson | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Amgen | 3 | $47 |
| Clovis Oncology, Inc. | 4 | $47 |
| AbbVie | 3 | $45 |
| Bayer | 3 | $41 |
| Exelixis Inc. | 2 | $40 |
| AVEO Pharmaceuticals, Inc. | 2 | $37 |
| Pfizer | 2 | $37 |
| Boehringer Ingelheim | 2 | $34 |
| AstraZeneca | 2 | $29 |
| Dendreon Pharmaceuticals LLC | 1 | $27 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| AMAG Pharmaceuticals, Inc. | 1 | $23 |
| Servier Pharmaceuticals LLC | 1 | $23 |
| Coherus Oncology, Inc. | 1 | $18 |
| Seagen Inc. | 1 | $17 |
| Acrotech Biopharma Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Tersera Therapeutics LLC | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $14 |
How this compares
$1,716 in reported general payments places this provider in the 60th percentile of 87 radiation oncology providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProgesteroneProgesterone, Micronized | 11 | $156 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Montgomery
- Alexander WhitleyMontgomery$441K
- Robert FranklinMontgomery$3K
- John JarboeMontgomery$3K
- Michael IngramMontgomery$2K
- Mayank PatelMontgomery$970
- Drexell BoggsBirmingham$35K
- Christopher JahrausAlabaster$28K
- Christopher WilleyBirmingham$13K
- Adam KoleBirmingham$11K
- William HixsonFairhope$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.